Celularity Inc (CELU)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.42
- As of
Kresmion compiles this page from CELU's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Celularity Inc (CELU): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-09-29.
See the full CELU dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for CELU on one page. Preview it with sample data, then open it live with a free account.
Preview the CELU dossierActive signals for CELU
- mediumEARNINGS_MISS
Q2-2025: Missed consensus by 33.3% - EPS $-1.02 vs $-0.765 estimate
- mediumEARNINGS_MISS
Q1-2025: Missed consensus by 9.8% - EPS $-0.84 vs $-0.765 estimate
- mediumEARNINGS_BEAT
Q3-2025: Beat consensus by 42.5% - EPS $-0.88 vs $-1.53 estimate
- mediumEARNINGS_BEAT
Q4-2025: Beat consensus by 44.4% - EPS $-0.85 vs $-1.53 estimate
- mediumEARNINGS_MISS
Missed consensus by 33.3% - EPS $-1.02 vs $-0.765 estimate
FREE, NO ACCOUNT
Every signal on CELU, as it fires
You are seeing 5 of 8 signals recorded on CELU since 2026-05-26.
The five above landed across 2 days. The other 3 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CELU (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 151190204 · 2026Q2 | $59K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CELU
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
CELU against its peers
CELU's operating margin of -230.9% ranks in the 79th percentile of 11 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-06-30.
| Metric | CELU | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 26.6M USD | 130000 USD | 84 | 15 |
| Operating margin | -230.9% | -5743.5% | 79 | 11 |
| Net margin | -345.4% | -5570.6% | 79 | 11 |
| Return on equity | n/a | -106.4% | n/a | 20 |
| 1 year | -30.4% | -53.2% | 64 | 20 |
Peers (25): ALDX, IBIO, ATHE, HYPD, PDSB, LONA, GUTS, GOSS, CNTB, EXOZ, INMB, MREO, SER, XLO, ANVS, TENX, BOLD, AURX, ACET, ELOX, DWTX, CRBU, TIL, CRVO, INKT. Fiscal periods ending between 2025-06-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (CELU: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow CELU on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to CELU for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.